Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 27

Sort by

Sort Order Select

Journal Articles

Influence of Different Genetic Alterations On the Engraftment Capacity and Serial Transplantation Efficiency of AML Patient-Derived Bone Marrow and Peripheral Blood Cells in NSG Mice

Julia Schüler, Peter Haas, MD, Kerstin Klingner, Björn W. Hackanson, MD, Heinz-Herbert Fiebig, Michael Lübbert, MD, PhD

Blood (2012) 120 (21): 3511.

https://doi.org/10.1182/blood.V120.21.3511.3511

Published: 2012

Journal Articles

CD34+ FISH As a New Method for Molecular-Cytogenetic Diagnostic From Peripheral Blood in MDS: Update of the Multicenter German Prospective Diagnostic Study

Blood (2012) 120 (21): 3816.

https://doi.org/10.1182/blood.V120.21.3816.3816

Published: 2012

Journal Articles

Phase I/II Study of Volasertib (BI 6727), An Intravenous Polo-Like Kinase (Plk) Inhibitor, in Patients with Acute Myeloid Leukemia (AML): Updated Results of the Dose Finding Phase I Part for Volasertib in Combination with Low-Dose Cytarabine (LD-Ara-C) and As Monotherapy in Relapsed/Refractory AML

Gesine Bug, MD, Carsten Müller-Tidow, MD, Richard F Schlenk, MD, Alwin Krämer, MD, Michael Lübbert, MD, PhD, Utz Krug, MD, Florian Voss, PhD, Tillmann Taube, MD, Holger Fritsch, PhD, Pilar Garin-Chesa, MD, PhD, Oliver G Ottmann, MD, Hartmut Döhner, MD

Blood (2011) 118 (21): 1549.

https://doi.org/10.1182/blood.V118.21.1549.1549

Published: 2011

Journal Articles

All- Trans Retinoic Acid Improves Outcome in Younger Adult Patients with Nucleophosmin-1 Mutated Acute Myeloid Leukemia – Results of the AMLSG 07-04 Randomized Treatment Trial

Blood (2011) 118 (21): 80.

https://doi.org/10.1182/blood.V118.21.80.80

Published: 2011

Journal Articles

Phase I/II Study of BI 6727 (volasertib), An Intravenous Polo-Like Kinase-1 (Plk1) Inhibitor, In Patients with Acute Myeloid Leukemia (AML): Results of the Dose Finding for BI 6727 In Combination with Low-Dose Cytarabine

Gesine Bug, MD, PhD, Richard F. Schlenk, MD, PhD, Carsten Müller-Tidow, MD, PhD, Michael Lübbert, MD, PhD, Alwin Krämer, MD, PhD, Frank Fleischer, Tillmann Taube, MD, Oliver G. Ottmann, MD, PhD, Hartmut Doehner, MD, PhD

Blood (2010) 116 (21): 3316.

https://doi.org/10.1182/blood.V116.21.3316.3316

Published: 2010

Journal Articles

Phase Ib Study of Oral Panobinostat In Combination with 5-Azacitidine (5-aza) In Patients with Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML)

Pierre Fenaux, MD, PhD, Daniel J DeAngelo, MD, PhD, Guillermo Garcia-Manero, MD, Michael Lübbert, MD, PhD, Anand P. Jillella, MD, Mikkael A. Sekeres, MD, MS, Ivo J. Winiger, MD, Margaret Squier, MD, PhD, Xiaodong Li, PhD, Oliver G. Ottmann, M.D.

Blood (2010) 116 (21): 4957.

https://doi.org/10.1182/blood.V116.21.4957.4957

Published: 2010

Journal Articles

Re-Expression of the AML1/ETO Target Gene LAT2/NTAL/LAB Results In Direct Interference with Myeloid Differentiation In AML1/ETO-Positive Cells

Jesus Duque-Afonso, Aitomi Essig, Leticia M Solari, Tobias Berg, MD, Heike L. Pahl, PhD, Michael Lübbert, MD, PhD

Blood (2010) 116 (21): 2474.

https://doi.org/10.1182/blood.V116.21.2474.2474

Published: 2010

Journal Articles

Survival, Prognostic Factors, and Rates of Leukemic Transformation in a Multicenter Study of 303 Untreated Patients with MDS and Del(5q).

Blood (2009) 114 (22): 945.

https://doi.org/10.1182/blood.V114.22.945.945

Published: 2009

Journal Articles

Selective HDAC6 Inhibition and Antileukemic Activity of the Novel HDAC Inhibitor ST80 in Myeloid Leukemia Cell Lines.

Bjorn W. Hackanson, MD, Leander Rimmele, Manfred Jung, PhD, Michael Lübbert, MD, PhD

Blood (2009) 114 (22): 4808.

https://doi.org/10.1182/blood.V114.22.4808.4808

Published: 2009

Journal Articles

Imatinib and Interferon-Alpha Maintenance Therapy for Patients with Philadelphia-Positive Acute Lymphoblastic Leukemia (Ph+ALL) Ineligible for Allogeneic Stem Cell Transplantation (SCT).

Heike Pfeifer, Barbara Wassmann, Andreas Käbisch, Michael Lübbert, MD, PhD, Lothar Leimer, MD, Aristoteles Giagounidis, Dieter Hoelzer, MD, PhD, Oliver G. Ottmann, MD

Blood (2009) 114 (22): 2042.

https://doi.org/10.1182/blood.V114.22.2042.2042

Published: 2009

Journal Articles

Acute Panmyelosis with Myelofibrosis: Clinicopathological and Molecular Features of a Rare Malignant Bone Marrow Disease.

Silke Kapp-Schwoerer, Renate Looser, Franz Schaub, Michael Hummel, Manfred Olschewski, Jens Hasskarl, Michael Lübbert, MD, PhD, Ulrich Germing, Radek C. Skoda, MD, Annette H Schmitt-Graeff

Blood (2009) 114 (22): 3101.

https://doi.org/10.1182/blood.V114.22.3101.3101

Published: 2009

Journal Articles

Phase I/II Study of BI 2536, An Intravenous Polo-Like Kinase-1 (Plk-1) Inhibitor, in Elderly Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML): First Results of a Multi-Center Trial

C. Müller-Tidow, MD, Gesine Bug, MD, Richard Schlenk, MD, Michael Lübbert, MD, PhD, Alwin Krämer, MD, Juergen Krauter, MD, David Nachbaur, MD, Peter Valent, MD, Tillmann Taube, MD, Gerd Munzert, MD, Kang-Hun Lee, MD, Hartmut Dohner, MD

Blood (2008) 112 (11): 2973.

https://doi.org/10.1182/blood.V112.11.2973.2973

Published: 2008

Journal Articles

Prognostic Impact of Additional Chromosomal Aberrations (ACA) to 5q- in Patients with primary Myelodysplastic Syndrome.

Blood (2008) 112 (11): 1649.

https://doi.org/10.1182/blood.V112.11.1649.1649

Published: 2008

Journal Articles

Prognostic Factors in Patients Receiving An Allogeneic Stem Cell Transplantation for Relapsed AML. Results of the Prospective AML 295 and 01/99 Studies

Jürgen Krauter, Gerhard Heil, Dieter Hoelzer, MD, PhD, Hans Martin, Oliver G. Ottmann, Jürgen Finke, Michael Lübbert, MD, PhD, Wolfgang Heit, Walter Fiedler, Lothar Kanz, MD, Günter Schlimok, Hartmut Kirchner, Aruna Raghavachar, Wolfram Brugger, Hartmut Döhner, Arnold Ganser, MD, PhD

Blood (2008) 112 (11): 344.

https://doi.org/10.1182/blood.V112.11.344.344

Published: 2008

Journal Articles

Low Dose Decitabine Versus Best Supportive Care in Elderly Patients with Intermediate or High Risk MDS Not Eligible for Intensive Chemotherapy: Final Results of the Randomized Phase III Study (06011) of the EORTC Leukemia and German MDS Study Groups

Pierre WijerMans, Stefan Suciu, Liliana Baila, Uwe Platzbecker, Aristoteles Giagounidis, Dominik Selleslag, Boris Labar, Helmut Salih, Filip Beeldens, Petra Muus, Theo de Witte, Michael Lübbert, MD, PhD

Blood (2008) 112 (11): 226.

https://doi.org/10.1182/blood.V112.11.226.226

Published: 2008

Journal Articles

Two Novel Somatic Mutations of the ATRX Gene in Female Patients with Acquired Alpha Thalassemia of Myelodysplastic Syndrome (ATMDS).

Peter S. Haas, MD, Michael Schwabe, MD, Chris Fisher, MD, PhD, Richard Gibbons, MD, Doug R. Higgs, MD, Emanuel Bissé, MD, Michael Lübbert, MD, PhD

Blood (2006) 108 (11): 1765.

https://doi.org/10.1182/blood.V108.11.1765.1765

Published: 2006

Journal Articles

Non-Intensive AML/MDS Treatment with Low-Dose Decitabine Prior to Reduced-Intensity Conditioning (RIC) and Allogeneic Blood Stem Cell Transplantation of Older Patients.

Michael Lübbert, MD, PhD, Hartmut Bertz, MD, PhD, Björn H. Rüter, MD, Roland H. Mertelsmann, MD, PhD, Jürgen Finke, MD, PhD

Blood (2006) 108 (11): 5257.

https://doi.org/10.1182/blood.V108.11.5257.5257

Published: 2006

Journal Articles

Efficacy of Decitabine in the Treatment of Patients with Chronic Myelomonocytic Leukemia (CMML).

P.W. Wijermans, MD, Michael Lübbert, MD, PhD, Maria R. Baer, MD, James L. Slack, MD

Blood (2006) 108 (11): 2676.

https://doi.org/10.1182/blood.V108.11.2676.2676

Published: 2006

Journal Articles

Hemoglobin F Induction Is Frequent during Low-Dose 5-aza-2′-Deoxycytidine Treatment of Older AML/MDS Patients.

Rainer Claus, MD, Björn Hackanson, MD, Lena Kasten, Björn Rüter, MD, Emmanuel Bisse, MD PhD, Dieter Pfeifer, PhD, Michael Lübbert, MD PhD

Blood (2006) 108 (11): 4573.

https://doi.org/10.1182/blood.V108.11.4573.4573

Published: 2006

Journal Articles

AML1/ETO-Mediated Lysozyme Repression Is Independently Relieved by Inhibitors of DNA Methylation and Histone Deacetylation.

Rainer Claus, MD, Manfred Fliegauf, PhD, Michael Stock, PhD, Jesus Duque, Mateusz Kolanczyk, PhD, Michael Lübbert, MD PhD

Blood (2006) 108 (11): 4310.

https://doi.org/10.1182/blood.V108.11.4310.4310

Published: 2006

NARROW

Influence of Different Genetic Alterations On the Engraftment Capacity and Serial Transplantation Efficiency of AML Patient-Derived Bone Marrow and Peripheral Blood Cells in NSG Mice

CD34+ FISH As a New Method for Molecular-Cytogenetic Diagnostic From Peripheral Blood in MDS: Update of the Multicenter German Prospective Diagnostic Study

Phase I/II Study of Volasertib (BI 6727), An Intravenous Polo-Like Kinase (Plk) Inhibitor, in Patients with Acute Myeloid Leukemia (AML): Updated Results of the Dose Finding Phase I Part for Volasertib in Combination with Low-Dose Cytarabine (LD-Ara-C) and As Monotherapy in Relapsed/Refractory AML

All- Trans Retinoic Acid Improves Outcome in Younger Adult Patients with Nucleophosmin-1 Mutated Acute Myeloid Leukemia – Results of the AMLSG 07-04 Randomized Treatment Trial

Phase I/II Study of BI 6727 (volasertib), An Intravenous Polo-Like Kinase-1 (Plk1) Inhibitor, In Patients with Acute Myeloid Leukemia (AML): Results of the Dose Finding for BI 6727 In Combination with Low-Dose Cytarabine

Phase Ib Study of Oral Panobinostat In Combination with 5-Azacitidine (5-aza) In Patients with Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML)

Re-Expression of the AML1/ETO Target Gene LAT2/NTAL/LAB Results In Direct Interference with Myeloid Differentiation In AML1/ETO-Positive Cells

Survival, Prognostic Factors, and Rates of Leukemic Transformation in a Multicenter Study of 303 Untreated Patients with MDS and Del(5q).

Selective HDAC6 Inhibition and Antileukemic Activity of the Novel HDAC Inhibitor ST80 in Myeloid Leukemia Cell Lines.

Imatinib and Interferon-Alpha Maintenance Therapy for Patients with Philadelphia-Positive Acute Lymphoblastic Leukemia (Ph+ALL) Ineligible for Allogeneic Stem Cell Transplantation (SCT).

Acute Panmyelosis with Myelofibrosis: Clinicopathological and Molecular Features of a Rare Malignant Bone Marrow Disease.

Phase I/II Study of BI 2536, An Intravenous Polo-Like Kinase-1 (Plk-1) Inhibitor, in Elderly Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML): First Results of a Multi-Center Trial

Prognostic Impact of Additional Chromosomal Aberrations (ACA) to 5q- in Patients with primary Myelodysplastic Syndrome.

Prognostic Factors in Patients Receiving An Allogeneic Stem Cell Transplantation for Relapsed AML. Results of the Prospective AML 295 and 01/99 Studies

Low Dose Decitabine Versus Best Supportive Care in Elderly Patients with Intermediate or High Risk MDS Not Eligible for Intensive Chemotherapy: Final Results of the Randomized Phase III Study (06011) of the EORTC Leukemia and German MDS Study Groups

Two Novel Somatic Mutations of the ATRX Gene in Female Patients with Acquired Alpha Thalassemia of Myelodysplastic Syndrome (ATMDS).

Non-Intensive AML/MDS Treatment with Low-Dose Decitabine Prior to Reduced-Intensity Conditioning (RIC) and Allogeneic Blood Stem Cell Transplantation of Older Patients.

Efficacy of Decitabine in the Treatment of Patients with Chronic Myelomonocytic Leukemia (CMML).

Hemoglobin F Induction Is Frequent during Low-Dose 5-aza-2′-Deoxycytidine Treatment of Older AML/MDS Patients.

AML1/ETO-Mediated Lysozyme Repression Is Independently Relieved by Inhibitors of DNA Methylation and Histone Deacetylation.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only